Screener
Vaxcyte, Inc. PCVX Accrued Manufacturing Costs
Accrued Manufacturing Costs at other companies
Other financials
Where this comes from
Reported directly by Vaxcyte, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.
The source filing: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 4:12 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001649094-26-000017
| Line item | March 31,2026 | December 31, 2025 |
|---|---|---|
| Liabilities and Stockholders' Equity | ||
| Current liabilities: | ||
| Accounts payable | $63,060 | $70,904 |
| Accrued compensation | 7,986 | 23,000 |
| Accrued contract manufacturing expenses | 134,704 | 74,654 |
| Accrued expenses | 30,247 | 31,068 |
| Operating lease liabilities — current | 6,085 | 6,124 |
| Total current liabilities | 242,082 | 205,750 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Vaxcyte, Inc.'s accrued manufacturing costs?
- Vaxcyte, Inc. (PCVX) reported accrued manufacturing costs of $7.99M in Q1 2026.
- How has Vaxcyte, Inc.'s accrued manufacturing costs changed year-over-year?
- Vaxcyte, Inc.'s accrued manufacturing costs increased by 33.3% year-over-year, from $5.99M to $7.99M.
- What is the long-term trend for Vaxcyte, Inc.'s accrued manufacturing costs?
- Over 5 years (2020 to 2025), Vaxcyte, Inc.'s accrued manufacturing costs has grown at a 140.8% compound annual growth rate (CAGR), from $284K to $23M.
Ask your AI about Vaxcyte, Inc.'s accrued manufacturing costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude